Tolerability of Antiandrogens in the Treatment of Prostate Cancer
about
Bicalutamide-associated fulminant hepatotoxicity.An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases.Evaluating the use of early hormonal therapy in patients with localised or locally advanced prostate cancer.Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.Case study: management of advanced prostate cancer with soft tissue metastases.The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
P2860
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2004
@uk
name
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@en
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@nl
type
label
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@en
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@nl
prefLabel
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@en
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@nl
P2860
P1433
P1476
Tolerability of Antiandrogens in the Treatment of Prostate Cancer
@en
P2093
R.-O. Fourcade
P2860
P356
10.1080/1561095042000191655
P577
2004-03-01T00:00:00Z